Safinamide: A Review in Parkinson’s Disease

• Published in: CNS drugs Vol. 31; no. 2; pp. 169 - 176
• Main Authors: Blair, Hannah A., Dhillon, Sohita
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.02.2017; Springer Nature B.V
• Subjects: Adis Drug Evaluation; Alanine - administration & dosage; Alanine - adverse effects; Alanine - analogs & derivatives; Alanine - pharmacology; Amine oxidase (flavin-containing); Antiparkinson Agents - administration & dosage; Antiparkinson Agents - adverse effects; Antiparkinson Agents - pharmacology; Benzylamines - administration & dosage; Benzylamines - adverse effects; Benzylamines - pharmacology; Bioavailability; Clinical trials; Dopamine; Dopamine receptors; Dose-Response Relationship, Drug; Drug dosages; Drug Therapy, Combination; Dyskinesia; Glutamatergic transmission; Humans; Levodopa; Levodopa - administration & dosage; Medicine; Medicine & Public Health; Metabolism; Metabolites; Monoamine Oxidase Inhibitors - administration & dosage; Monoamine Oxidase Inhibitors - adverse effects; Monoamine Oxidase Inhibitors - pharmacology; Motor task performance; Movement disorders; Neurodegenerative diseases; Neurology; Neurosciences; Parkinson Disease - drug therapy; Parkinson Disease - physiopathology; Parkinson's disease; Pharmacotherapy; Psychiatry; Psychopharmacology; Quality of Life; Rodents; Studies; Urine; Entacapone; Levodopa; Motor Fluctuation; Little Square Mean; Rasagiline

Safinamide (Xadago ® ) is an orally active, selective, reversible monoamine oxidase-B inhibitor with both dopaminergic and non-dopaminergic (glutamatergic) properties. In the EU, safinamide is approved for the treatment of mid- to late-stage fluctuating Parkinson’s disease (PD) as add-on therapy to...